Compare Novo Nordisk A/S (NVO) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Standard Lithium Ltd — how do they compare? Novo Nordisk A/S trades at $44.71 (market cap $200.69B), while Standard Lithium Ltd trades at $2.37 (market cap $589.88M). The key difference: Novo Nordisk A/S is far larger — about 340.2× Standard Lithium Ltd's market cap, and Novo Nordisk A/S pays a 3.98% dividend while Standard Lithium Ltd pays none. Which is the better fit depends on your goals.
| NVO | SLI | |
|---|---|---|
Market Cap | $200.69B | $589.88M |
Sector | Health | Basic Materials |
52-Week High | $63.98 | $5.65 |
52-Week Low | $35.29 | $1.93 |
Enterprise Value | $215.49B | $452.79M |
Dividend Yield | 3.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
Standard Lithium (SLI) trades at $2.40, down 0.83% today, with a bullish technical signal despite negative profitability metrics. The company shows progress with recent DOE clearance and key customer agreements, including LG Energy Solution, while maintaining 100% analyst buy ratings. Cash flow remains positive primarily from financing activities, though operational cash flow is negative as the company invests heavily in lithium project development.
The outlook hinges on successful project execution and Final Investment Decision for the Arkansas lithium project, which could unlock $250 million in government funding. Key risks include execution delays and negative profitability, but strong institutional interest and supportive government policies for critical minerals provide upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
